数字中医药（英文）2020，Vol.3Issue(1)：1-10,10.DOI:10.1016/j.dcmed.2020.03.001
基于网络药理学方法预测水晶兰苷治疗结直肠癌的作用机制
Mechanism Prediction of Monotropein for the Treatment of Colorectal Cancer by Network Pharmacology Analysis
摘要
Abstract
Objective To discover the pharmacological mechanisms of monotropein in colorectal cancer by network pharmacology methods.Methods The main-candidate-target network was constructed by the prediction of targets of monotropein, collection of therapeutic targets of colorectal cancer drugs, and construction of the target network and layers of screening. The data were interpreted by pathway enrichment and target score calculation. Results This study: (1) Demonstrated the potential of monotropein to be a multi-target drug against colorectal cancer using a computational approach; (2) Discovered 10 candidate targets of monotropein, among which protein kinase B (AKT1) exhibited the highest relevance and importance to colorectal cancer and proto-oncogene tyrosine-protein kinase Src (SRC), Bruton's tyrosine kinase (BTK), and heat shock protein HSP 90-alpha (HSP90AA1) also exhibited high relevance; (3) Observed 32 possible pathways related to the effects of monotropein on colorectal cancer, which might explain the mechanism of its action; and (4) Established a method to assess the importance of targets in the network. Conclusions This study offered clues for the mechanism of the bioactivities of monotropein against colorectal cancer by network analysis. Monotropein has the potential to be a multi-target drug against colorectal cancer, which lays the foundation for its clinical applications and further study.关键词
结直肠癌/水晶兰苷/网络药理分析/靶点/AKT1Key words
Colorectal cancer/Monotropein/Network pharmacology/Target/Protein kinase B (AKT1)引用本文复制引用
李翀,侯少贞,周华..基于网络药理学方法预测水晶兰苷治疗结直肠癌的作用机制[J].数字中医药（英文）,2020,3(1):1-10,10.基金项目
We thank for the funding support from the Joint Research Fund for Overseas Chinese, Hong Kong and Macao Young Scholars of National Science Foundation of China (No. 81929003), the Science and Technology Development Fund, Macau SAR (No. 0027/2017/AMJ) and the National Key Research and Development Program of China (No. 2017YFE0119900). （No. 81929003）
